You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Phase 2 Combination

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Solid Tumor, CDKN2A, NSCLC Trial (Milademetan, Atezolizumab)

Withdrawn
  • Advanced Solid Tumor
  • +9 more
  • (no location specified)
Oct 16, 2023

Acute Myeloid Leukemia Trial in Houston (ASTX727, ASTX029-01)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    MD Anderson Cancer Center
Oct 27, 2023

Locally Advanced Unresectable or Metastatic Esophageal Cancer Trial (Futibatinib, Pembrolizumab, Cisplatin)

Not yet recruiting
  • Locally Advanced Unresectable or Metastatic Esophageal Cancer
  • (no location specified)
Jul 6, 2023

Meningioma Trial in Vandœuvre-lès-Nancy (Everolimus)

Not yet recruiting
  • Meningioma
  • Vandœuvre-lès-Nancy, Grand Est, France
  • +1 more
Nov 8, 2023

HER2-positive Breast Cancer Trial (Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab))

Not yet recruiting
  • HER2-positive Breast Cancer
  • Tucatinib (Combination of tucatinib-Oral VP16-trastuzumab)
  • (no location specified)
Jul 20, 2023

Renal Cell Carcinoma Trial in Houston (Tivozanib, Nivolumab)

Not yet recruiting
  • Renal Cell Carcinoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Pancreatic Cancer Metastatic Trial (C3 (Metformin, Simvastatin, and Digoxin))

Not yet recruiting
  • Pancreatic Cancer Metastatic
  • C3 (Metformin, Simvastatin, and Digoxin)
  • (no location specified)
Sep 1, 2023

Cancer, Tumor, Solid, Malignant Tumor Trial (OR502, Cemiplimab)

Not yet recruiting
  • Cancer
  • +6 more
  • (no location specified)
Oct 16, 2023

MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors Trial (AMG 193, IDE397)

Not yet recruiting
  • MTAP-null Non-Small-Cell Lung Cancer
  • MTAP-null Solid Tumors
  • (no location specified)
Jul 27, 2023

HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)

Completed
  • HER2-positive Breast Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023

Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer Trial (T-Dxd(Trastuzmab deruxtecan), Ramucirumab)

Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction (GEJ) Cancer
  • T-Dxd(Trastuzmab deruxtecan), Ramucirumab
  • (no location specified)
Jun 7, 2023

Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

Not yet recruiting
  • Relapsed or Refractory Hodgkin Lymphoma
  • Peripheral T Cell Lymphoma
  • (no location specified)
May 30, 2023

Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

Not yet recruiting
  • Multiple Myeloma in Relapse
  • Multiple Myeloma, Refractory
  • (no location specified)
Oct 30, 2023

Ovarian Cancer Trial (Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in

Not yet recruiting
  • Ovarian Cancer
  • Autologous genetically modified ADP-A2M4CD8 cells
  • Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
  • (no location specified)
Jan 31, 2023

Colorectal Cancer, GIST Trial (DCC-3116, Ripretinib, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • GIST
  • (no location specified)
Jul 14, 2023

Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

Not yet recruiting
  • Breast Cancer
  • Marseille, France
    Institut Paoli Calmettes
Aug 9, 2023

Advanced Renal Cell Carcinoma Trial (Botensilimab, Balstilimab, Ipilimumab)

Not yet recruiting
  • Advanced Renal Cell Carcinoma
  • (no location specified)
Jun 23, 2023

Gastroesophageal Adenocarcinoma Trial (toripalimab FOLFOX)

Not yet recruiting
  • Gastroesophageal Adenocarcinoma
  • toripalimab FOLFOX
  • (no location specified)
Aug 3, 2023

HER2 Gene Mutation Trial in Shanghai (Injection of IAH0968+Gemcitabine+Cisplatin, Gemcitabine+Cisplatin)

Recruiting
  • HER2 Gene Mutation
  • Injection of IAH0968+Gemcitabine+Cisplatin
  • Gemcitabine+Cisplatin
  • Shanghai, China
    Fudan University Affiliated Zhongshan Hospital
Aug 7, 2023

IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

Not yet recruiting
  • IDH1-mutant Cholangiocarcinoma
  • (no location specified)
Jun 29, 2023

Large B-cell Lymphoma Trial in Houston (Prednisone, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Large B-cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Sep 19, 2023

Efficacy Trial in Seoul (Oral sotorasib + IV Panitumumab)

Active, not recruiting
  • Efficacy
  • Oral sotorasib + IV Panitumumab
  • Seoul, Korea, Republic of
    Korea University Anam Hospital
Aug 14, 2023

Cholangiocarcinoma Trial (GNS561 + Trametinib)

Not yet recruiting
  • Cholangiocarcinoma
  • GNS561 + Trametinib
  • (no location specified)
May 22, 2023

Immunoglobulin A Nephropathy Trial in Denver (Sparsentan)

Not yet recruiting
  • Immunoglobulin A Nephropathy
  • Denver, Colorado
    Travere Investigational Site
May 12, 2023

Melanoma Trial in Beijing (OH2 injection, HX008 injection)

Recruiting
  • Melanoma
  • OH2 injection
  • HX008 injection
  • Beijing, Beijing, China
    Peking University Cancer Hospital
Jan 28, 2023